REVASCOR - CHF Insurance Coverage, page-57

Just following up @dachopper's post -- this is what SI said during the last conference call on 28 May:

"In December, the Phase III trial for advanced heart failure surpassed the number of primary endpoint events required for trial completion. The final study visits for all surviving patients have been completed. There is an ongoing quality review of all the data, it will be completed shortly at the study sites. The data readout is planned in mid 2020 and the results may support regulatory approval in the US. "

There is a similar statement at slide 29 of the accompanying slide pack. Looks like they will be looking to get FDA approval on the strength of one phase 3 only. That could mean they get Revscor to US market sometime in 2021. Pretty amazing if they can pull that off.